Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
MK-7246 is an antagonist of the prostaglandin D2 (PGD2; Item No. 12010) receptor CRTH2/DP2 (Ki = 2.5 nM).1 It is selective for CRTH2/DP2 over DP1, the PGF2α receptor (FP), the PGI2 receptor (IP), and the thromboxane A2 (TP) receptor (Kis = 373, >25,100, >23,030, and 3,804 nM, respectively), as well as the PGE2 receptor subtypes 1-4 (EP1-4; Kis = 7,668-23,330 nM). MK-7246 inhibits 13,14-dihydro-15-keto-PGD2-induced inhibition of cAMP formation in HEK293 cells expressing human CRTH2/DP2 (IC50 = 3 nM). It also inhibits 13,14-dihydro-15-keto-PGD2-induced eosinophil shape change (IC50 = 2.2 nM) and CD11b upregulation on eosinophils and basophils in isolated human whole blood (IC50s = 6.2 and 5.4 nM, respectively). MK-7246 (1 mg/kg) decreases antigen-induced late-phase bronchoconstriction and completely prevents airway hyperresponsiveness in sheep.
WARNING This product is not for human or veterinary use.
1. Pharmacological characterization of MK-